Tumor Antigen by Immunoassay - CA 125 — NCD 130 | CMS Coverage Update

CMS modified NCD 130 for CA 125 tumor antigen testing, effective March 7, 2026. Here's what billing teams need to know about coverage criteria, exclusions, and documentation requirements.

The Centers for Medicare & Medicaid Services updated NCD 130 in the NCD 130 Medicare system, governing CA 125 immunoassay testing for epithelial ovarian carcinoma and related malignancies. This coverage policy draws a hard line between covered monitoring uses and non-covered diagnostic uses — a distinction that drives a significant share of CA 125 billing claim denials. The policy does not list specific CPT or HCPCS codes in its code tables, so your billing team must verify applicable codes with your Medicare Administrative Contractor.

Quick-Reference Table

CMS CA 125 Coverage Criteria and Medical Necessity Requirements 2026

The real issue with CA 125 billing is that the test looks the same on a claim regardless of why it was ordered. CMS draws a sharp line between covered and non-covered uses — and the difference comes down entirely to medical necessity documentation.

Pre-operative baseline testing is covered. CMS covers a CA 125 level as part of the initial pre-operative work-up when a woman presents with a suspicious pelvic mass. The purpose here is to establish a baseline for post-operative monitoring — not to diagnose. That distinction matters. If your ordering provider documents the test as a diagnostic tool to evaluate whether a pelvic mass is malignant, you're outside the coverage policy.

Post-treatment monitoring is covered. CMS covers three serum CA 125 levels during the first month after initial surgery and/or chemotherapy for ovarian carcinoma. These three draws measure the CA 125 half-life, which carries prognostic weight. Your documentation must tie each draw to this specific clinical purpose — not just "follow-up lab work."

Completion-of-chemotherapy assessment is covered. A CA 125 level at the end of a chemotherapy course is covered as an index of residual disease. This is a distinct covered indication with its own clinical rationale. Make sure the claim documentation reflects that context.

Surveillance testing follows a defined schedule. CMS covers surveillance CA 125 measurements at these intervals: every three months for two years, every six months for the following three years, and annually thereafter. If your billing team sees CA 125 claims that don't fit this schedule, that's a flag. A claim for a surveillance draw at four weeks post-completion of the two-year window will draw scrutiny.

Active disease monitoring is covered. For patients with advanced or recurrent disease, CMS covers CA 125 levels before each treatment cycle as an indicator of response to therapy. Prior authorization is not explicitly required under this NCD, but your MAC may have local requirements — verify before billing.

Reimbursement for CA 125 testing hinges on clear documentation of which covered indication applies. If the chart note doesn't specify that this is a baseline draw, a post-treatment half-life measurement, a surveillance draw, or a pre-cycle assessment, your claim is exposed.

CMS CA 125 Exclusions and Non-Covered Indications

This is where most CA 125 billing problems originate. The policy is explicit, and there's no gray area here.

Differential diagnosis of a pelvic mass is not covered. CMS specifically excludes CA 125 testing to aid in the differential diagnosis of patients with a pelvic mass. The policy cites insufficient sensitivity and specificity as the clinical rationale. This is a hard exclusion — not a documentation problem you can fix after the fact.

Signs and symptoms suggestive of malignancy are not covered. If a provider orders CA 125 to evaluate a patient who presents with symptoms that might indicate cancer — bloating, pelvic pain, elevated CA 125 suspicion — that's not a covered indication. The test is not covered for evaluating signs or symptoms suggestive of malignancy. Full stop.

The practical implication: if your practice sees patients referred for evaluation of a pelvic mass or vague abdominal symptoms, and CA 125 is ordered at that visit, the claim will not meet medical necessity under this coverage policy. A claim denial in that scenario is nearly certain if it reaches a medical necessity review.

One marker, one malignancy. CMS states that in general, a single tumor marker suffices for following a patient with one of these malignancies. If your oncologist orders both CA 125 and another tumor marker for the same patient and same indication, expect scrutiny on the second test. Document the clinical rationale for any multi-marker approach.

Coverage Indications at a Glance

CMS CA 125 Billing Guidelines and Action Items 2026

The effective date of March 7, 2026 makes this immediate. Don't treat this as a future project.

CPT, HCPCS, and ICD-10 Codes for CA 125 Tumor Antigen Under NCD 130

Coverage Status Note

NCD 130 does not list specific CPT, HCPCS, or ICD-10 codes in its published code tables. CMS directs billing teams to the quarterly Covered Code List published by each MAC, referenced in the Medicare Claims Processing Manual, Chapter 120.

Do not assume a code is covered under NCD 130 without verifying it on your MAC's current Covered Code List. Contact your MAC directly or access their LCD and coverage article database to confirm the specific laboratory CPT codes applicable to CA 125 immunoassay testing in your region.

Your MAC may also have a Local Coverage Determination that supplements or further restricts NCD 130. Check for any active LCD from your MAC before updating your charge capture.